Thus, a comprehensive interpretation of both studies supports that the residual risk of thromboembolic events among AF patients with diabetes requiring insulin therapy is not insignificant in a real-world setting, even in the background of chronic OAC and regardless of the OAC type (VKAs or NOACs). The gene discussed is INS; the disease is atrial fibrillation.